True believer Alex Waislitz is 'still optimistic Mesoblast will succeed'
As shares in stem-cell developer Mesoblast hit six-year lows, hanging on has become something for the totally committed, like fund manager Alex Waislitz, who says: 'It's been a journey with plenty of ups and downs'.